Branster,
I believe much has to do with what the Journal has to say. DI appears to have indicated that presentations to date only tell a small part of the picture. I for one have been pushing the fact that all patients in the trial haven't been accounted for, if they were the minimum of 50 who'd have to lived for over 7 years per Dr. Ashkan's remarks on the Top 100 median, or near 5 years on Dr. Liau's SNO presentation nearly 3 years prior would show on the K-M plots. Clearly if 50 or more are alive at 7 + years the percentage surviving in the total trial moves up substantially.
I have no idea what they were holding back, or why, but it's impossible to have the median survival for the Top 100 at 7+ years if 50 patients haven't lived beyond 7 years. It's very possible that these patients are no longer considered GBM patients as the classification of the disease was changed, but they'd still represent brain cancer patients who got tremendous benefits from the vaccine and all of them should be getting it once it's approved.
I believe that $2 or more should have been where we were by the presentation at NYAS, it's sad that allegations by AdamF and others could create the doubt that they did, but that's water under the bridge. When all the facts are known I believe we will be substantially higher than $2. By all the facts I mean what the company has been doing since the quiet period began. How close are we to regulatory submissions, or has it already been done. Likewise, what's the current status of the FlaskWorks units certification, when do they believe they'll have it. I don't believe that anyone here can say with certainty whether we'll gain approval from one or more regulator this year, but when we learn where the company stands we may learn a lot more about the. Of course approval is never a sure thing, but that said, it seems like the U.K. has been eager to get DCVax-L into the hands of patients, I believe if anyone grants approval quickly it will be the U.K. I believe the others won't be all that far behind unless commercial production is what they're waiting for.
Gary
